General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0XGLSR
ADC Name
NOV0712-DM4
Synonyms
NOV0712 DM4
   Click to Show/Hide
Organization
Daiichi Sankyo Co., Ltd.;
Drug Status
Investigative
Indication
In total 2 Indication(s)
Ovarian cancer [ICD11:2C73]
Investigative
Renal cell carcinoma [ICD11:2C90]
Investigative
Drug-to-Antibody Ratio
3.6
Antibody Name
Anti-CDH6 mAb NOV0712
 Antibody Info 
Antigen Name
Cadherin-6 (CDH6)
 Antigen Info 
Payload Name
Mertansine DM4
 Payload Info 
Therapeutic Target
Microtubule (MT)
 Target Info 
Linker Name
Sulfo-SPDB
 Linker Info 
Conjugate Type
Random conjugation through nucleophilic lysines.
Combination Type
Soravtansine
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 9 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 0
%
CVCL_3509
Ovarian clear cell adenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 0
%
CVCL_3509
Ovarian clear cell adenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 3.1
%
CVCL_0465
Ovarian serous adenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 6.77
%
CVCL_0479
Ovarian mixed germ cell tumor
Tumor Growth Inhibition value (TGI) 
≈ 9.52
%
CVCL_1051
Renal cell carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 12.03
%
CVCL_0479
Ovarian mixed germ cell tumor
Tumor Growth Inhibition value (TGI) 
≈ 23.91
%
CVCL_1051
Renal cell carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 30.02
%
CVCL_1051
Renal cell carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 72.3
%
CVCL_0465
Ovarian serous adenocarcinoma
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
1.00-10.00
nM
CVCL_0479
Ovarian mixed germ cell tumor
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 9 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 0.00% (Day 13) Negative CDH6 expression (CDH6-)
Method Description
The CDH6-negative human ovarian tumor cell line ES-2 was subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate NOV0712-DM4 was intravenously administered at doses of 1 mg/kg to thetail of each mouse.
In Vivo Model ES-2 CDX model
In Vitro Model Ovarian clear cell adenocarcinoma ES-2 cells CVCL_3509
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 0.00% (Day 13) Negative CDH6 expression (CDH6-)
Method Description
The CDH6-negative human ovarian tumor cell line ES-2 was subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate NOV0712-DM4 was intravenously administered at doses of 3 mg/kg to thetail of each mouse.
In Vivo Model ES-2 CDX model
In Vitro Model Ovarian clear cell adenocarcinoma ES-2 cells CVCL_3509
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 3.10% (Day 28) Positive CDH6 expression (CDH6+++/++)
Method Description
The CDH6-positive human ovarian tumor cell line OVCAR-3 was subcutane-ously inoculated at a dose of 10,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 22 of grouping, theantibody-drug conjugate NOV0712-DM4 was intravenously administered at doses of 1 mg/kg to the tail of each mouse.
In Vivo Model OVCAR-3 CDX model
In Vitro Model Ovarian serous adenocarcinoma OVCAR-3 cells CVCL_0465
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 6.77% (Day 21) Positive CDH6 expression (CDH6+++/++)
Method Description
The CDH6-positive human ovarian tumor cell line PA-1 was subcutaneously inoculatedat a dose of 8,500,000 cells to the right flank region of eachfemale nude mouse (Day 0). On the day 11 of grouping, the antibody-drug conjugate NOV0712-DM4 was intravenously administered at doses of 3 mg/kg to the tail of each mouse.
In Vivo Model PA-1 CDX model
In Vitro Model Ovarian mixed germ cell tumor PA-1 cells CVCL_0479
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 9.52% (Day 23) Positive CDH6 expression (CDH6+++/++)
Method Description
The CDH6-positive human renal cell tumor cell line786-0 was subcutaneously inoculated at a dose of 5,000,000 cells to the right flank regionof each male SCID mouse (Day 0). On the day 20 of grouping, the anti-body-drug conjugate NOV0712-DM4 was intravenously administered at doses of 1 mg/kg to thetail of each mouse.
In Vivo Model 786-O CDX model
In Vitro Model Renal cell carcinoma 786-O cells CVCL_1051
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 12.03% (Day 21) Positive CDH6 expression (CDH6+++/++)
Method Description
The CDH6-positive human ovarian tumor cell line PA-1 was subcutaneously inoculatedat a dose of 8,500,000 cells to the right flank region of eachfemale nude mouse (Day 0). On the day 11 of grouping, the antibody-drug conjugate NOV0712-DM4 was intravenously administered at doses of 1 mg/kg to the tail of each mouse.
In Vivo Model PA-1 CDX model
In Vitro Model Ovarian mixed germ cell tumor PA-1 cells CVCL_0479
Experiment 7 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 23.91% (Day 23) Positive CDH6 expression (CDH6+++/++)
Method Description
The CDH6-positive human renal cell tumor cell line786-0 was subcutaneously inoculated at a dose of 5,000,000 cells to the right flank regionof each male SCID mouse (Day 0). On the day 20 of grouping, the anti-body-drug conjugate NOV0712-DM4 was intravenously administered at doses of 3 mg/kg to thetail of each mouse.
In Vivo Model 786-O CDX model
In Vitro Model Renal cell carcinoma 786-O cells CVCL_1051
Experiment 8 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 30.02% (Day 24) Positive CDH6 expression (CDH6+++/++)
Method Description
The CDH6-positive human renal cell tumor cell line 786-O was subcutaneously inoculated at a dose of 5,000,000 cells to the right flank regionof each male SCID mouse (Day 0). On the day 18 of grouping, NOV0712-DM4 was intravenously administered at a dose of 3 mg/kg to the tail of each mouse.
In Vivo Model 786-O CDX model
In Vitro Model Renal cell carcinoma 786-O cells CVCL_1051
Experiment 9 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 72.30% (Day 28) Positive CDH6 expression (CDH6+++/++)
Method Description
The CDH6-positive human ovarian tumor cell line OVCAR-3 was subcutane-ously inoculated at a dose of 10,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 22 of grouping, theantibody-drug conjugate NOV0712-DM4 was intravenously administered at doses of 3 mg/kg to the tail of each mouse.
In Vivo Model OVCAR-3 CDX model
In Vitro Model Ovarian serous adenocarcinoma OVCAR-3 cells CVCL_0465
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 1.00-10.00 nM Positive CDH6 expression (CDH6+++/++)
Method Description
CDH6-positive human ovarian tumor cell line PA-1 was seeded over a 96-well plate at 2,000 cells/100 L/well in MEM medium supplemented with 10% FBS, and the cells were then cultured overnight. On the next day, each of the 4 humanized hG019-drug conjugates or NOV0712-DM4 was added to the cells.
In Vitro Model Ovarian mixed germ cell tumor PA-1 cells CVCL_0479
References
Ref 1 Anti-cdh6 antibody and anti-cdh6 antibody-drug conjugate.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.